Golpimec 0,5 mg kapsler, hårde Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

golpimec 0,5 mg kapsler, hårde

neuraxpharm sweden ab - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg

Tysabri Den Europæiske Union - dansk - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - multipel sclerose - selektive immunosuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Mitoxantron "Ebewe" 2 mg/ml koncentrat til infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

mitoxantron "ebewe" 2 mg/ml koncentrat til infusionsvæske, opløsning

ebewe pharma ges.m.b.h. nfg. kg - mitoxantronhydrochlorid - koncentrat til infusionsvæske, opløsning - 2 mg/ml

Zeposia Den Europæiske Union - dansk - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Mitoxantron "Ebewe" 2 mg/ml koncentrat til infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

mitoxantron "ebewe" 2 mg/ml koncentrat til infusionsvæske, opløsning

orifarm a/s - mitoxantronhydrochlorid - koncentrat til infusionsvæske, opløsning - 2 mg/ml

Tyruko Den Europæiske Union - dansk - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.